Diagnostic aptitude of West Nile virus-like particles expressed in insect cells

2018 ◽  
Vol 91 (3) ◽  
pp. 233-238 ◽  
Author(s):  
Belén Rebollo ◽  
Javier Sarraseca ◽  
Mª José Rodríguez ◽  
Antonio Sanz ◽  
Miguel Ángel Jiménez-Clavero ◽  
...  
Vaccine ◽  
2010 ◽  
Vol 28 (40) ◽  
pp. 6588-6596 ◽  
Author(s):  
Naohiro Ohtaki ◽  
Hidehiro Takahashi ◽  
Keiko Kaneko ◽  
Yasuyuki Gomi ◽  
Toyokazu Ishikawa ◽  
...  

2004 ◽  
Vol 78 (21) ◽  
pp. 11605-11614 ◽  
Author(s):  
Frank Scholle ◽  
Yvette A. Girard ◽  
Qizu Zhao ◽  
Stephen Higgs ◽  
Peter W. Mason

ABSTRACT A trans-packaging system for West Nile virus (WNV) subgenomic replicon RNAs (repRNAs), deleted for the structural coding region, was developed. WNV repRNAs were efficiently encapsidated by the WNV C/prM/E structural proteins expressed in trans from replication-competent, noncytopathic Sindbis virus-derived RNAs. Infectious virus-like particles (VLPs) were produced in titers of up to 109 infectious units/ml. WNV VLPs established a single round of infection in a variety of different cell lines without production of progeny virions. The infectious properties of WNV and VLPs were indistinguishable when efficiencies of infection of a number of different cell lines and inhibition of infection by neutralizing antibodies were determined. To investigate the usefulness of VLPs to address biological questions in vivo, Culex pipiens quinquefasciatus mosquitoes were orally and parenterally infected with VLPs, and dissected tissues were analyzed for WNV antigen expression. Antigen-positive cells in midguts of orally infected mosquitoes were detected as early as 2 days postinfection and as late as 8 days. Intrathoracic inoculation of VLPs into mosquitoes demonstrated a dose-dependent pattern of infection of secondary tissues and identified fat body, salivary glands, tracheal cells, and midgut muscle as susceptible WNV VLP infection targets. These results demonstrate that VLPs can serve as a valuable tool for the investigation of tissue tropism during the early stages of infection, where virus spread and the need for biosafety level 3 containment complicate the use of wild-type virus.


2011 ◽  
Vol 174 (1-2) ◽  
pp. 131-135 ◽  
Author(s):  
Naohiro Ohtaki ◽  
Hidehiro Takahashi ◽  
Keiko Kaneko ◽  
Yasuyuki Gomi ◽  
Toyokazu Ishikawa ◽  
...  

2010 ◽  
Vol 10 (1) ◽  
pp. 165 ◽  
Author(s):  
Rie Hasebe ◽  
Tadaki Suzuki ◽  
Yoshinori Makino ◽  
Manabu Igarashi ◽  
Satoko Yamanouchi ◽  
...  

2004 ◽  
Vol 190 (12) ◽  
pp. 2104-2108 ◽  
Author(s):  
Ming Qiao ◽  
Mundrigi Ashok ◽  
Kristen A. Bernard ◽  
Gustavo Palacios ◽  
Z. Hong Zhou ◽  
...  

Virology ◽  
2016 ◽  
Vol 496 ◽  
pp. 186-193 ◽  
Author(s):  
Travis J. Taylor ◽  
Fernando Diaz ◽  
Robert C. Colgrove ◽  
Kristen A. Bernard ◽  
Neal A. DeLuca ◽  
...  

2005 ◽  
Vol 49 (12) ◽  
pp. 4980-4988 ◽  
Author(s):  
Francesc Puig-Basagoiti ◽  
Tia S. Deas ◽  
Ping Ren ◽  
Mark Tilgner ◽  
David M. Ferguson ◽  
...  

ABSTRACT Many flaviviruses cause significant human disease worldwide. The development of flavivirus chemotherapy requires reliable high-throughput screening (HTS) assays. Although genetic systems have been developed for many flaviviruses, their usage in antiviral HTS assays has not been well explored. Here we compare three cell-based HTS assays for West Nile virus (WNV) drug discovery: (i) an assay that uses a cell line harboring a persistently replicating subgenomic replicon (containing a deletion of viral structural genes), (ii) an assay that uses packaged virus-like particles containing replicon RNA, and (iii) an assay that uses a full-length reporting virus. A Renilla luciferase gene was engineered into the replicon or into the full-length viral genome to monitor viral replication. Potential inhibitors could be identified through suppression of luciferase signals upon compound incubation. The antiviral assays were optimized in a 96-well format, validated with known WNV inhibitors, and proved useful in identifying a new inhibitor(s) through HTS of a compound library. In addition, because each assay encompasses multiple but discrete steps of the viral life cycle, the three systems could potentially be used to discriminate the mode of action of any inhibitor among viral entry (detected by assays ii and iii but not by assay i), replication (including viral translation and RNA synthesis; detected by assays i to iii), and virion assembly (detected by assay iii but not by assays i and ii). The approaches described in this study should be applicable to the development of cell-based assays for other flaviviruses.


ASHA Leader ◽  
2004 ◽  
Vol 9 (9) ◽  
pp. 10-13
Author(s):  
Susan Brady ◽  
Rhonda Miserendino ◽  
Noel Rao
Keyword(s):  

2005 ◽  
Vol 39 (8) ◽  
pp. 10
Author(s):  
PATRICE WENDLING
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document